article thumbnail

Biofourmis hits unicorn status after $300m Series D funding

AsiaTechDaily

Register Biofourmis , a Sigapore-founded digital therapeutics firm , announced that it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. Bookmark ( 0 ) Please login to bookmark Username or Email Address Password Remember Me No account yet?

article thumbnail

FDA: Orientation for Early Stage Startups

Y Combinator

Whether you’re pursuing an IND or an IDE, you’ll have to fully explain what you want to study, who your investigators are, how safe the product is, what type of patient consent you’re requesting, and what institutional review board (IRB) has reviewed and cleared your studies. Marketing Approval.

startup 61